EA200300882A1 - Способ лечения демиелинизирующих заболеваний или состояний - Google Patents

Способ лечения демиелинизирующих заболеваний или состояний

Info

Publication number
EA200300882A1
EA200300882A1 EA200300882A EA200300882A EA200300882A1 EA 200300882 A1 EA200300882 A1 EA 200300882A1 EA 200300882 A EA200300882 A EA 200300882A EA 200300882 A EA200300882 A EA 200300882A EA 200300882 A1 EA200300882 A1 EA 200300882A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
conditions
compounds
useful
diseases
Prior art date
Application number
EA200300882A
Other languages
English (en)
Other versions
EA011319B1 (ru
Inventor
Крэйг П. Смит
Мишель П. Рэтбоун
Маргарет Петти
Дэвид Рэмп
Original Assignee
Авентис Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Инк. filed Critical Авентис Фармасьютикалз Инк.
Publication of EA200300882A1 publication Critical patent/EA200300882A1/ru
Publication of EA011319B1 publication Critical patent/EA011319B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение относится к N-(пиридинил)-1H-индол-1-аминам формулы I, которые имеют уникальную комбинацию блокирующих свойств как в отношении калиевых, так и в отношении натриевых каналов. Указанные соединения полезны для лечения демиелинизирующих заболеваний и состояний, таких как рассеянный склероз, повреждение спинного мозга, травматическое повреждение головного мозга и удар. Соединения также полезны для реабилитации после удара, лечения раздражения и дисфункции мочевого пузыря и лечения невропатической боли и боли, индуцированной хемокинами.Отчет о международном поиске был опубликован 2003.02.20.
EA200300882A 2001-02-15 2002-02-14 Способ лечения демиелинизирующих заболеваний или состояний EA011319B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions
PCT/US2002/005501 WO2002064126A2 (en) 2001-02-15 2002-02-14 Method of treating of demyelinating diseases or conditions

Publications (2)

Publication Number Publication Date
EA200300882A1 true EA200300882A1 (ru) 2003-12-25
EA011319B1 EA011319B1 (ru) 2009-02-27

Family

ID=23024747

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200300882A EA011319B1 (ru) 2001-02-15 2002-02-14 Способ лечения демиелинизирующих заболеваний или состояний
EA200600896A EA012409B1 (ru) 2001-02-15 2002-02-14 Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200600896A EA012409B1 (ru) 2001-02-15 2002-02-14 Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря

Country Status (39)

Country Link
US (10) US6967210B2 (ru)
EP (1) EP1368031A2 (ru)
JP (3) JP2004518711A (ru)
KR (3) KR100951542B1 (ru)
CN (2) CN100522164C (ru)
AP (1) AP1749A (ru)
AR (1) AR035750A1 (ru)
AU (3) AU2002247200B9 (ru)
BR (1) BR0207272A (ru)
CA (1) CA2438712A1 (ru)
CO (1) CO5390085A1 (ru)
CR (1) CR7023A (ru)
CZ (1) CZ20032172A3 (ru)
EA (2) EA011319B1 (ru)
EC (1) ECSP024218A (ru)
EE (1) EE200300363A (ru)
GB (1) GB0119435D0 (ru)
HK (1) HK1080361B (ru)
HR (1) HRP20030652A2 (ru)
HU (1) HUP0303203A3 (ru)
IL (2) IL157341A0 (ru)
MA (1) MA26152A1 (ru)
ME (1) MEP21208A (ru)
MX (1) MXPA03006110A (ru)
MY (1) MY157745A (ru)
NO (1) NO20033622L (ru)
NZ (4) NZ539159A (ru)
OA (1) OA12549A (ru)
PA (1) PA8540101A1 (ru)
PE (1) PE20040175A1 (ru)
PL (1) PL363638A1 (ru)
SG (1) SG134170A1 (ru)
SK (1) SK10392003A3 (ru)
TR (4) TR200800693T2 (ru)
TW (1) TWI325319B (ru)
UA (2) UA80394C2 (ru)
WO (1) WO2002064126A2 (ru)
YU (1) YU62903A (ru)
ZA (1) ZA200306124B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
EP1480631B1 (en) * 2002-12-20 2007-08-01 Dynogen Pharmaceuticals Inc. Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators
US20040209960A1 (en) * 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
CN102822979B (zh) * 2010-03-26 2015-08-26 株式会社半导体能源研究所 半导体器件
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
JP2014503596A (ja) * 2011-01-28 2014-02-13 アコーダ セラピューティクス，インコーポレーテッド 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US11730769B2 (en) 2017-12-22 2023-08-22 Children's Medical Center Corporation Compositions and methods for Williams Syndrome (WS) therapy
CN116723870A (zh) * 2021-01-20 2023-09-08 拉什大学医学中心 球形细胞脑白质营养不良症或克拉伯病的改良治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (en) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
NZ234726A (en) * 1989-08-02 1992-01-29 Hoechst Roussel Pharma 2,3-dihydro-1-(pyridinylamino)-indoles and pharmaceutical compositions
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
CA2318817A1 (en) * 1998-01-29 1999-08-05 Bristol-Myers Squibb Company Phosphate derivatives of diaryl 1,3,4-oxadiazolone
WO2001004091A1 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
CO5390085A1 (es) 2004-04-30
HK1080361B (zh) 2009-10-30
UA80394C2 (en) 2007-09-25
US7179821B2 (en) 2007-02-20
EP1368031A2 (en) 2003-12-10
AU2002247200B2 (en) 2007-12-13
OA12549A (en) 2006-06-05
CR7023A (es) 2003-11-17
AU2008201179B2 (en) 2009-08-20
NO20033622D0 (no) 2003-08-14
YU62903A (sh) 2006-05-25
HUP0303203A3 (en) 2007-11-28
US20090209594A1 (en) 2009-08-20
AU2009238332A1 (en) 2009-12-10
NZ556697A (en) 2009-01-31
ECSP024218A (es) 2003-09-24
US20050234105A1 (en) 2005-10-20
KR20090005254A (ko) 2009-01-12
US20030105150A1 (en) 2003-06-05
PE20040175A1 (es) 2004-03-29
US7230015B2 (en) 2007-06-12
HRP20030652A2 (en) 2005-06-30
EA012409B1 (ru) 2009-10-30
US20050159456A1 (en) 2005-07-21
AP2003002834A0 (en) 2003-09-30
US20090281147A1 (en) 2009-11-12
TR200800691T2 (tr) 2008-03-21
NZ539159A (en) 2006-11-30
PL363638A1 (en) 2004-11-29
EA200600896A1 (ru) 2006-08-25
CN100522164C (zh) 2009-08-05
AR035750A1 (es) 2004-07-07
MEP21208A (en) 2010-06-10
KR100951542B1 (ko) 2010-04-09
ZA200306124B (en) 2004-11-08
US6967210B2 (en) 2005-11-22
TR200301330T2 (tr) 2004-12-21
US20060025452A1 (en) 2006-02-02
US20040157889A1 (en) 2004-08-12
AU2008201179A1 (en) 2008-04-03
JP2004518711A (ja) 2004-06-24
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
HUP0303203A2 (hu) 2003-12-29
MXPA03006110A (es) 2005-07-01
CN1529598A (zh) 2004-09-15
TR200800693T2 (tr) 2008-07-21
NO20033622L (no) 2003-10-06
JP2010120958A (ja) 2010-06-03
EA011319B1 (ru) 2009-02-27
HK1080361A1 (en) 2006-04-28
WO2002064126A3 (en) 2003-02-20
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
PA8540101A1 (es) 2003-09-05
CZ20032172A3 (cs) 2004-01-14
SG134170A1 (en) 2007-08-29
IL157341A (en) 2010-11-30
US7534803B2 (en) 2009-05-19
JP2009185045A (ja) 2009-08-20
CN1679564A (zh) 2005-10-12
KR100951540B1 (ko) 2010-04-09
KR20090005255A (ko) 2009-01-12
WO2002064126A2 (en) 2002-08-22
EE200300363A (et) 2003-10-15
AP1749A (en) 2007-06-13
IL157341A0 (en) 2004-02-19
BR0207272A (pt) 2004-02-10
NZ527011A (en) 2005-07-29
KR20040014459A (ko) 2004-02-14
UA88773C2 (ru) 2009-11-25
NZ544720A (en) 2007-08-31
US20090270458A1 (en) 2009-10-29
CA2438712A1 (en) 2002-08-22
GB0119435D0 (en) 2001-10-03
US20090209595A1 (en) 2009-08-20
MA26152A1 (fr) 2004-07-01
AU2002247200B9 (en) 2008-07-10
US20040157888A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
EA200300882A1 (ru) Способ лечения демиелинизирующих заболеваний или состояний
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200400022A1 (ru) Соединения и способы лечения или предупреждения инфекций flavivirus
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
EA200301253A1 (ru) Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
ATE417856T1 (de) Motilidverbindungen
PT94151A (pt) Processo para a preparacao de dihidrodibenzotiazepinas uteis como agentes antiespasmodicos
SE0101082D0 (sv) Novel use
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
EA200201234A1 (ru) Производные сульфонамида
TH60984A (th) วิธีรักษาโรค หรือสภาวะจากการสูญเสียไมอีลิน
UY27206A1 (es) Método de tratamiento de condiciones o enfermedades desmielinizantes
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60108775D1 (de) Methode zur behandlung von schlaganfall
RU93035807A (ru) Способ лечения юношеского эпифизиолиса

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU